Latest "Biomarker discovery Driving technologies" News Stories

06:08 EDT 1st September 2015 | BioPortfolio

Here are the most relevant search results for "Biomarker discovery Driving technologies" found in our extensive news archives from over 250 global news sources.

More Information about Biomarker discovery Driving technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biomarker discovery Driving technologies for you to read. Along with our medical data and news we also list Biomarker discovery Driving technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biomarker discovery Driving technologies Companies for you to search.

Showing "Biomarker discovery Driving technologies" News Articles 1–25 of 6,100+


Integrating biomarkers in colorectal cancer trials in the West and China

Predictive biomarkers are invaluable for successful and cost-effective treatment of cancer, however, biomarker discovery is difficult and requires multiple independent studies to identify suitable predictors of efficacy. Clinical trials performed in ...

Medical News Today: Ovarian cancer treatment set to improve following biomarker discovery

The discovery of a biomarker that predicts the response to chemotherapy in patients with the most malignant form of ovarian cancer will help lead to better treatment options.

Biomarker Summit Europe 2015 on October 5-8, 2015 in Berlin, Germany

The summit will address the latest developments in the biomarker arena from discovery to translation to commercialization. Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of ...

Potential Biomarker Discovered for Lung Cancer

To date, no biomarker has been found for lung cancer. This discovery could help quick and cost-effective diagnosis at an earlier stage of the disease, improving survival rates.

Biomarker Discovery Makes Urine Test for Early Stage Pancreatic Cancer Possible

A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers from Queen Mary University of London have found. The discovery could lead to a non-invasive, inexpensive test to screen people at high risk of developing the disease.Read more

Medical News Today: Lung cancer blood test steps closer with new biomarker discovery

Researchers have discovered a blood biomarker that is 'highly effective' in distinguishing between people with and without nonsmall cell lung cancer.

Key DNA discovery points to new clinical biomarker in predicting breast cancer risk

Scientists part-funded by Breast Cancer Now, Human Genetics Foundation (HuGeF), and the Cancer Council Victoria (Melbourne, Australia) have identified a new biomarker in the blood that could help identify more women at an increased risk of breast can...

Alternative splicing as a biomarker and potential target for drug discovery

Blood test for osteoarthritis on the cards thanks to new discovery

The first blood test for osteoarthritis could soon be available following the discovery of a biomarker linked to both rheumatoid and osteoarthritis. The findings could lead to people being tested for osteoarthritis and diagnosed several years before the onset of physical symptoms. Citrullinated proteins (CPs) are the focus of the research. We already know that […] The post Blood test for ost...

Berg: Using artificial intelligence for drug discovery

Berg, a Boston biotech, has a strong artificial intelligence platform for drug discovery. It has several drugs in its pipeline, and is leading an effort to discover the very first biomarker for pancreatic cancer.

Transgenomic – genetic biomarker identification

Transgenomic is a biotech company identifying genetic biomarker using proprietary methods and assays. Transgenomic – genetic biomarker identification Transgenomic is advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies. This biotech company is a global … Continue reading → Cet article Transgenomic – g...

CheckMate-057 Trial: The Future of PD-L1 as a Biomarker

Dr H. Jack West discusses one of the hottest topics at ASCO 2015: the evolving role of PD-L1 as an immunotherapy biomarker. Medscape Oncology

Alexion, Blueprint to develop, market rare genetic disease treatments

Blueprint Medicines is partnering with Alexion to use its kinase-focused drug-discovery technology to research, develop and m -More- Biomarkers Summit 2015 Register for the Biomarkers Summit 2015 on March 18-20, 2015 in San Diego, CA. Meet ...

Driving customer centricity at headquarters through defining and driving the right KPIs

At last years DigiPharm 2014 event,  Debraj Dasgupta , Team Leader – Oncology, Metabolism, Immunology, Boehringer Ingelheim GmbH,  gave the presentation “Driving customer centricity at headquarters through ... The post Driving customer centricity at headquarters through defining and driving the right KPIs appeared first on Total Biopharma.

New immunoregulation and biomarker

Clinicians at LMU have elucidated a mechanism involved in determining the lifespan of antibody-producing cells, and identified a promising new biomarker for monitoring autoimmune diseases like multiple sclerosis and lupus erythematosus.

Aptagen – aptamer-beacon

Aptagen is a biotech company proposing aptamer products and services as reagents, diagnostic and biomarker discovery tools. Aptamers are used in drug discovery, targeted delivery for therapeutics or bioindustrial applications. Aptagen – aptamer-beacon Aptamers (synthetic antibodies) are ligands of RNA, … Continue reading → Cet article Aptagen – aptamer-beacon est apparu en ...

Novel Biomarker Could Aid Early NSCLC Detection

A new study identified the molecule known as N1,N12-diacetylspermine as a potential biomarker for early-stage non–small-cell lung cancer.

Urine test for early stage pancreatic cancer possible after biomarker discovery

(Pancreatic Cancer Research Fund) A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, UK researchers have found. The discovery could lead to a non-invasive, inexpensive test to screen peo...

Potential Biomarker for Alzheimer’s Found

Current tests for Alzhemier's disease are costly and inefficient. Scientists may have found a blood biomarker that could be used to test more people who are at-risk of developing the condition.

Retrospective Sample Collection for Biomarker Discovery, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - March 17, 2015) - Join speakers from Almac Diagnostics, including Dr. Peter Kerr, Head of Project Management & Product Development, and Kinga Wojciechowska, Project Manager for Ethics/Tissue Collection, as they discuss sample access and profiling for biomarker discovery to help rescue or reposition drugs. The complimentary 60-minute broadcast takes place on Wednesda...

Discovery Life Sciences, Inc. introduces Magellan -- an Innovative WEB based Biobank delivering Human Biospecimens to advance Novel Biomarker tests in clinical development

LOS OSOS, Calif., July 14, 2015 /PRNewswire/ -- Discovery Life Sciences, Inc., a provider of essential clinical research products and services to the Life Sciences industry announced today that it has launched Magellan – an innovative online ordering platform for ready-to-deliver Human Biospecimens designed for Biopharmaceutical, Biotechnology and Medical Device companies who seek ...

Spit-and-Stick Test Could Be Biomarker for HNSCC

A much-needed biomarker for head and neck squamous cell carcinoma (HNSCC) that assesses tumor DNA shed in plasma and saliva is in the works. Medscape Medical News

The AAPS Journal: Calculations for Adjusting Endogenous Biomarker Levels During Analytical Recovery Assessments for Ligand-Binding Assay Bioanalytical Method Validation

Type: Original PaperIt is often necessary to adjust for detectable endogenous biomarker levels in spiked validation samples (VS) and in selectivity determinations during bioanalytical method validation for ligand-binding assays (LBA) with a matrix li...

New Biomarker Report from Amplion Describes Key Market Trends for Diagnostic Tests and Precision Medicine

It takes an average of 15 years for novel biomarkers to go from discovery to the clinic, this according to a new research report released today by Amplion Inc. The free report, titled “Market Trends for Biomarker-Based IVD Tests (2003-2014): Realizing the Promise of Precision Medicine,” analyzes key trends involving the development, regulatory...

Gut Denervation Occurs Sequentially in Parkinson's

A study using PET biomarker imaging showed denervation of the small intestine in prodromal PD, followed later by pancreatic denervation, suggesting PET may be a useful biomarker for early disease. Medscape Medical News


News Quicklinks